Objective:To investigate the role of clinical pharmacists in the management of pharmacological treatment for pancreatic cancer pain.Methods:A retrospective analysis was conducted on the clinical data of 58 inpatients diagnosed with pancreatic cancer associated pain at the Pancreas Center of Nanjing BenQ Hospital Affiliated to Nanjing Medical University from January 2023 to March 2023. The outcomes of pain control, quality of life (QOL), medication adherence, patient satisfaction with pain management, and trust in clinical pharmacists were compared before and after pharmacist intervention. Adverse drug reactions (ADRs) were also monitored.Results:The involvement of clinical pharmacists in pain medication management significantly reduced pain scores in 58 patients at 12, 24, and 48 hours after intervention compared to pre-intervention levels [(2.64±1.04), (2.72±1.12), and (2.17±0.96) vs (5.88±1.11)]. Pain scores at 48 hours after intervention were significantly lower than those at 12 and 24 hours. QOL scores significantly improved after the intervention [(38.53±7.03), (38.84±7.11), and (39.77±6.71) vs (32.48 ± 7.32)], with scores at 48 hours significantly higher than those at 12 and 24 hours. All the differences were statistically significant (all P value <0.05). After intervention, pain scores were negatively correlated with QOL scores, indicating that a significant reduction in pain was associated with a substantial improvement in quality of life. The proportion of patients with good medication adherence increased from 41.4% before the intervention to 86.2% after the intervention. Trust in clinical pharmacists rose from 70.7% to 100%, with a satisfaction rate of 98.2%. Among the 58 patients, 21 experienced ADRs, including constipation (29.0%), nausea (23.7%), vomiting (13.1%), somnolence (10.5%), dizziness (7.9%), diarrhea (7.9%), fatigue (5.3%), and delirium (2.6%). Conclusions:The involvement of clinical pharmacists in the pharmacological management of pain in pancreatic cancer could significantly reduce pain scores, improve patients' QOL, enhance medication adherence, and monitor ADRs, which may comprehensively promote rational and standardized pain management for pancreatic cancer patients.

Objective:To investigate the role of clinical pharmacists in the management of pharmacological treatment for pancreatic cancer pain.Methods:A retrospective analysis was conducted on the clinical data of 58 inpatients diagnosed with pancreatic cancer associated pain at the Pancreas Center of Nanjing BenQ Hospital Affiliated to Nanjing Medical University from January 2023 to March 2023. The outcomes of pain control, quality of life (QOL), medication adherence, patient satisfaction with pain management, and trust in clinical pharmacists were compared before and after pharmacist intervention. Adverse drug reactions (ADRs) were also monitored.Results:The involvement of clinical pharmacists in pain medication management significantly reduced pain scores in 58 patients at 12, 24, and 48 hours after intervention compared to pre-intervention levels [(2.64±1.04), (2.72±1.12), and (2.17±0.96) vs (5.88±1.11)]. Pain scores at 48 hours after intervention were significantly lower than those at 12 and 24 hours. QOL scores significantly improved after the intervention [(38.53±7.03), (38.84±7.11), and (39.77±6.71) vs (32.48 ± 7.32)], with scores at 48 hours significantly higher than those at 12 and 24 hours. All the differences were statistically significant (all P value <0.05). After intervention, pain scores were negatively correlated with QOL scores, indicating that a significant reduction in pain was associated with a substantial improvement in quality of life. The proportion of patients with good medication adherence increased from 41.4% before the intervention to 86.2% after the intervention. Trust in clinical pharmacists rose from 70.7% to 100%, with a satisfaction rate of 98.2%. Among the 58 patients, 21 experienced ADRs, including constipation (29.0%), nausea (23.7%), vomiting (13.1%), somnolence (10.5%), dizziness (7.9%), diarrhea (7.9%), fatigue (5.3%), and delirium (2.6%). Conclusions:The involvement of clinical pharmacists in the pharmacological management of pain in pancreatic cancer could significantly reduce pain scores, improve patients' QOL, enhance medication adherence, and monitor ADRs, which may comprehensively promote rational and standardized pain management for pancreatic cancer patients.

It is of important significant to predict the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus infection in clinic. Various risks scoring systems can achieve better prediction effect by integrating a variety of risk factors, but they still need to be perfected. Recent researches have found that some genotypes and genetic variations are associated with the occurrence of HCC and they can indicate the tumorigenesis of HCC. Some known or newly discovered indicators such as WFA⁺ -M2BP can be used to predict the occurrence of HCC independently or jointly. With the development of research, more genes, indicators as well as newly built scoring system will be utilized to predict the occurrence of HCC in clinic.